Compassionate use experience with gefitinib in poor performance (PS) patients with advanced non-small-cell lung cancer (NSCLC) treated in an expanded access program (EAP).

被引：0
|
作者：
Zinner, R
Govindan, R
Wozniak, AJ
Wade, JL
Belani, CP
Thienelt, CD
Hensing, TA
Reiling, RB
Natale, RB
Wiznitzer, I
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Washington, Sch Med, St Louis, MO USA
[3] Karmanos Canc Ctr, Detroit, MI USA
[4] Decatur Mem Hosp, Decatur, IL USA
[5] UPMC, Pittsburgh, PA USA
[6] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[7] Evanston NW Healthcare, Evanston, IL USA
[8] Presbyterian Canc Ctr, Charlotte, NC USA
[9] Cedars Sinai Comprehens Canc Ctr, Los Angeles, CA USA
[10] Lynn Reg Canc Ctr W, Boca Raton, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7082
引用
收藏
页码：636S / 636S
页数：1
相关论文
共 50 条
  • [31] Gefitinib for Chinese patients with advanced non-small-cell lung cancer
    Xiaotong, Z
    Longyun, L
    Xinlin, MU
    LUNG CANCER, 2004, 45 : S79 - S79
  • [32] PREDICTIVE FACTORS ASSOCIATED WITH GEFITINIB RESPONSE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)
    Xu, F.
    Zhou, T.
    Duan, J.
    ANNALS OF ONCOLOGY, 2012, 23 : 47 - 47
  • [33] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [34] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer (NSCLC)
    Chen, Lian
    Chen, Rui
    Zhu, Zhe
    Zhang, Yichen
    Wen, Zhengwei
    Li, Yun
    Li, Xiaoming
    Luo, Yuwen
    Ma, Liyu
    Lin, Shuguang
    Chen, Xin
    CHINESE JOURNAL OF CANCER RESEARCH, 2014, 26 (04) : 466 - 470
  • [35] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    F Cappuzzo
    S Bartolini
    G L Ceresoli
    S Tamberi
    A Spreafico
    L Lombardo
    V Gregorc
    L Toschi
    C Calandri
    E Villa
    L Crinò
    British Journal of Cancer, 2004, 90 : 82 - 86
  • [36] Retrospective analysis of patients with advanced non-small cell lung cancer who participated in the extended access program (EAP) of gefitinib
    Kang, J. -H.
    Kang, S. Y.
    Kim, H. T.
    Lee, J. S.
    Shim, B. Y.
    Park, B. -B.
    Park, J. O.
    Park, K.
    Shin, S. W.
    Heo, D. S.
    Kim, D. -W.
    Ryoo, B. -Y.
    Lee, J. C.
    Na, I. I.
    Kim, S. -W.
    Suh, C.
    Cho, B. C.
    LUNG CANCER, 2006, 52 : S23 - S24
  • [37] Predictive factors associated with gefitinib response in patients with advanced non-small-cell lung cancer(NSCLC)
    Lian Chen
    Rui Chen
    Zhe Zhu
    Yichen Zhang
    Zhengwei Wen
    Yun Li
    Xiaoming Li
    Yuwen Luo
    Liyu Ma
    Shuguang Lin
    Xin Chen
    Chinese Journal of Cancer Research, 2014, 26 (04) : 466 - 470
  • [38] Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)
    Figueiredo, A.
    Almeida, M. A.
    Almodovar, M. T.
    Alves, P.
    Araujo, A.
    Araujo, D.
    Barata, F.
    Barradas, L.
    Barroso, A.
    Brito, U.
    Camacho, E.
    Canario, D.
    Cardoso, T.
    Chaves, A.
    Costa, L.
    Cunha, J.
    Duarte, J.
    Estevinho, F.
    Felizardo, M.
    Fernandes, J. P.
    Ferreira, L.
    Fidalgo, P.
    Freitas, C.
    Garrido, P.
    Gil, N.
    Hasmucrai, D.
    Jesus, E.
    Lopes, J. A.
    de Macedo, J. E.
    Meleiro, A.
    Neveda, R.
    Nogueira, F.
    Pantorotto, M.
    Parente, B.
    Pego, A.
    Rocha, M.
    Roque, J.
    Santos, C.
    Saraiva, J.
    Silva, E.
    Silva, S.
    Simoes, S.
    Soares, M.
    Teixeira, E.
    Timoteo, T.
    Hespanhol, V
    PULMONOLOGY, 2020, 26 (01): : 10 - 17
  • [39] Use of Cetuximab After Failure of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer
    Wu, Jenn-Yu
    Yang, Chih-Hsin
    Hsu, Ya-Chieh
    Yu, Chong-Jen
    Chang, Shih-Han
    Shih, Jin-Yuan
    Yang, Pan-Chyr
    CLINICAL LUNG CANCER, 2010, 11 (04) : 257 - 263
  • [40] Gefitinib ('Iressa', ZD1839) for patients with advanced non-small-cell lung cancer treated in the 'Iressa' Expanded Access Programme at a single institution in Brazil
    Katz, A
    Smaletz, O
    Simon, SD
    Rene, GC
    Hoff, PM
    Tabacof, J
    BRITISH JOURNAL OF CANCER, 2003, 89 : S29 - S29
12345